Metastatic breast cancer
Research is centered on hormone receptor-positive, HER2-negative disease in men and postmenopausal women, with particular attention to PIK3CA-mutated cases that have progressed after prior endocrine therapy.
- Hormone receptor-positive breast cancer
- HER2-negative disease
- PIK3CA mutation
The clinical focus includes treatment-resistant advanced breast cancer and the management of disease that remains dependent on endocrine pathways.
Targeted therapy in breast oncology
The sponsor’s research activity involves alpelisib in combination with fulvestrant, reflecting interest in PI3K pathway-directed treatment for advanced breast cancer.
- Alpelisib
- Fulvestrant
- PI3K signaling
Attention is directed toward targeted endocrine-based regimens used in metastatic oncology.
Treatment tolerability and metabolic safety
Clinical interest includes hyperglycemia associated with PI3K inhibitor therapy, with emphasis on grade 3 or 4 adverse events and overall treatment tolerability.
- Hyperglycemia
- Adverse event monitoring
- Therapy-related toxicity
The research landscape also covers the balance between antitumor activity and metabolic complications in patients receiving targeted treatment.
Supportive nutrition and medication timing
Another area of interest is the relationship between drug administration timing, fasting, and low-carbohydrate diet measures in the context of breast cancer treatment.
- Medication timing
- Fasting
- Dietary modification
This includes evaluation of how supportive lifestyle measures may influence both toxicity and treatment effectiveness in advanced disease.
